참고문헌 (38)

1. Nat Rev Clin Oncol Brudno 15 31 2018 10.1038/nrclinonc.2017.128 Chimeric antigen receptor T cell therapies for lymphoma 

   상세보기

2. 2008 Guidance for industry: CGMP for phase 1 investigational drugs 

3. Gee 1 2009 Cell therapy: cGMP facilities and manfacturing 

4. 2008 Guidance for FDA reviewers and sponsors: content and review of Chemistry, manufacturing, and Control (CMC) information for human somatic cell therapy investigational new drug applications (INDs) 

5. 2004 Guidance for FDA reviewers and sponsors: content and review of Chemistry, manufacturing, and Control (CMC) information for human gene therapy investigational new drug applications (INDs) 

6. 2011 Guidance for industry: potency tests for cellular and gene therapy products. ) 

7. Transfus Med Rev Fesnak 30 139 2016 10.1016/j.tmrv.2016.03.001 CAR-T cell therapies from the transfusion medicine perspective 

   상세보기

8. Allen ES, Stroncek DF, Ren J, Eder AF, West KA, Fry TJ, et al. Autologous lymphapheresis for the production of chimeric antigen receptor T cells. 

9. Nat Biotechnol Themeli 31 928 2013 10.1038/nbt.2678 Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy 

   상세보기

10. J Transl Med Stroncek 15 1160 2017 10.1186/s12967-017-1160-5 Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells 

    상세보기

11. Molec Ther Oncolytics Wang 3 16015 2016 10.1038/mto.2016.15 Clinical manufacturing of CAR-T cells: foundation of a promising therapy 

    상세보기

12. Immunobiology Zeng 219 583 2014 10.1016/j.imbio.2014.03.003 Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens 

    상세보기

13. J Clin Invest Savoldo 121 1822 2011 10.1172/JCI46110 CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients 

    상세보기

14. Wang A31 2015 Comparison of CTS dynabeadsc CD3/CD28, Miltenyi TransAct CD3/28 and ExpAct beads for large-scale CAR-T cell manufacturing 

15. Bashour 2015 Abstract # 1901 American society of hematology meeting Functional characterization of a T cell stimulation reagent for the production of therapeutic chimeric antigen receptor T cells 

16. Mol Ther Wang 24 Supplement 1 2014 Evaluation of Miltenyi ExpAct and TransAct CD3/28 beads for CAR-T cell manufacturing 

17. Biomedicines Morgan 4 9 2016 10.3390/biomedicines4020009 Genetic modification of T cells 

    상세보기

18. Mol Ther Methods Clin Dev Levine 17 92 2017 10.1016/j.omtm.2016.12.006 Global manufacturing of CAR-T cell therapy 

    상세보기

19. Proc Natl Acad Sci USA Pear 90 8392 1993 10.1073/pnas.90.18.8392 Production of high-titer helper-free retroviruses by transient transfection 

    상세보기

20. Mol Ther Methods Clin Dev Merten 13 16017 2016 10.1038/mtm.2016.17 Production of lentiviral vectors 

    상세보기

21. Curr Gene Therapy Deichmann 13 469 2013 10.2174/15665232113136660004 Biosafety considerations using gamma-retroviral vectors in gene therapy 

    

22. Hum Mol Genet Aronovich 20 R14 2011 10.1093/hmg/ddr140 The Sleeping Beauty transposon system: a non-viral vector for gene therapy 

    상세보기

23. Cytotherapy Saito 16 1257 2014 10.1016/j.jcyt.2014.05.022 Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome -positive acute lymphoblastic leukemia 

    상세보기

24. Trans Res Hackett 161 265 2013 10.1016/j.trsl.2012.12.005 Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy 

    상세보기

25. J Vis Exp Huls 1 72 2013 Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood 

26. J Clin Invest Kebriael 126 3363 2016 10.1172/JCI86721 Phase 1 trials using Sleeping Beauty to generated CD19-specififc CAR-T cells 

    상세보기

27. Blood Bajgain 120 348 2012 10.1182/blood.V120.21.348.348 Optimizing the manufacture of CAR-T cells for clinical applications 

    상세보기

28. Hollyman D, Stefanski J, Przbylowski M, Bartido S, Borquez-Ojeda O, Taylor C et al. Manufacturing validation of biologically functional T cells targeted to CD19. 

29. Blood Zhu 128 5724 2016 10.1182/blood.V128.22.5724.5724 CAR-T Cell production using the CliniMACS prodigy system 

    상세보기

30. Cytotherapy Mock 18 1002 2016 10.1016/j.jcyt.2016.05.009 Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy 

    상세보기

31. Molec Ther Nickolay 24 Supplement 1 S180 2016 10.1016/S1525-0016(16)33264-6 Automated lentiviral Transduction of T Cells with CARS using the CliniMACS prodigy 

    상세보기

32. Hum Gene Ther Lock 28 914 2017 10.1089/hum.2017.111 Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use 

    상세보기

33. 57 1133 2017 WP2 Production of clinical grade EURE-CART cells 

34. 2011 Guidance for industry: process validation: general principles and practices 

35. J Immunother Lee 41 19 2018 Preclinical optimization of a CD20 chimeric antigen receptor vector and culture conditions 

36. Bersenev 

37. Cancer J Kakarla 20 151 2014 10.1097/PPO.0000000000000032 CAR-T cells for solid tumors: armed and ready to go? 

    상세보기

38. 2017 Draft guidance for industry: expedited programs for regenerative medicine therapies for serious conditions